German Biotech allies with Genentech in battle for Cancer Vaccine

21/09/2016 - 3 minutes

BioNTech has turned up the heat in the race to bring an mRNA immunotherapy for cancer to the clinic. The German biotech has partnered with American giant Genentech in a massive deal with almost €300M upfront.

images-2Europe’s largest private biotech, BioNTech, has partnered up with Genentech to produce individualized mRNA-based cancer therapies. The collaboration aims to apply Genentech’s expertise as a world leader in immuno-oncology to BioNTech’s proprietary mRNA cancer vaccine technology. The ultimate goal of the partnership is to bring a variety of highly specific cancer treatments tailored to individual patient needs to clinical trials.

Genentech paid €280M in upfront and milestone payments to gain access to BioNTech’s technology. The two companies will split manufacturing duties and developmental costs but divvy up commercial rights on a case-by-case basis: if Genentech decides not to avail itself of its share for a product, BioNTech will take over.

But this German biotech is no slouch. The company has developed a cancer vaccine platform that it calls IVAC (Individualized Vaccines Against Cancer) MUTANOME,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

Support Us

Become a Member